Mechanisms of Drug Resistance to Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2023 Feb 27

PMID 36845142

Authors

Kexun Zhou

Shuo Li

Yi Zhao

Ke Cheng

Affiliations

Soon will be listed here.

Abstract

Immune checkpoint inhibitors (ICIs) in the form of anti-CTLA-4 and anti-PD-1/PD-L1 have become the frontier of cancer treatment and successfully prolonged the survival of patients with advanced non-small cell lung cancer (NSCLC). But the efficacy varies among different patient population, and many patients succumb to disease progression after an initial response to ICIs. Current research highlights the heterogeneity of resistance mechanisms and the critical role of tumor microenvironment (TME) in ICIs resistance. In this review, we discussed the mechanisms of ICIs resistance in NSCLC, and proposed strategies to overcome resistance.

Citing Articles

Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy.

Almawash S Cancers (Basel). 2025; 17(5).

PMID: 40075727 PMC: 11899125. DOI: 10.3390/cancers17050880.

Immune Checkpoints Are New Therapeutic Targets in Regulating Cardio-, and Cerebro-Vascular Diseases and CD4Foxp3 Regulatory T Cell Immunosuppression.

Shao Y, Yang W, Nanayakkara G, Saaoud F, Ben Issa M, Xu K Int J Drug Discov Pharm. 2025; 3(4).

PMID: 39926714 PMC: 11804271. DOI: 10.53941/ijddp.2024.100022.

Role of the TME in immune checkpoint blockade resistance of non-small cell lung cancer.

Dai Y, Tian X, Ye X, Gong Y, Xu L, Jiao L Cancer Drug Resist. 2025; 7():52.

PMID: 39802954 PMC: 11724356. DOI: 10.20517/cdr.2024.166.

Towards precision medicine: design considerations for nanozymes in tumor treatment.

Li X, Hu J, Zhao Q, Yao W, Jing Z, Jin Z J Transl Med. 2024; 22(1):1033.

PMID: 39550581 PMC: 11568558. DOI: 10.1186/s12967-024-05845-w.

Prognostic Indicators for Precision Treatment of Non-Small Cell Lung Carcinoma.

Ghosh D, McDonald H, Dutta R, Krishnan K, Thilakan J, Paul M Cells. 2024; 13(21.

PMID: 39513892 PMC: 11545304. DOI: 10.3390/cells13211785.

References

Sharma P, Hu-Lieskovan S, Wargo J, Ribas A . Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. Cell. 2017; 168(4):707-723. PMC: 5391692. DOI: 10.1016/j.cell.2017.01.017. View

Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N . The cancer metabolic reprogramming and immune response. Mol Cancer. 2021; 20(1):28. PMC: 7863491. DOI: 10.1186/s12943-021-01316-8. View

Wu K, Lin K, Li X, Yuan X, Xu P, Ni P . Redefining Tumor-Associated Macrophage Subpopulations and Functions in the Tumor Microenvironment. Front Immunol. 2020; 11:1731. PMC: 7417513. DOI: 10.3389/fimmu.2020.01731. View

Munn D, Mellor A . IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance. Trends Immunol. 2016; 37(3):193-207. PMC: 4916957. DOI: 10.1016/j.it.2016.01.002. View

Oh S, Kim S, Keam B, Kim T, Kim D, Heo D . Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment. Sci Rep. 2021; 11(1):19712. PMC: 8492653. DOI: 10.1038/s41598-021-99311-y. View

Edwards D, Ngwa V, Raybuck A, Wang S, Hwang Y, Kim L . Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer. J Clin Invest. 2020; 131(4. PMC: 7880417. DOI: 10.1172/JCI140100. View

Chang C, Qiu J, OSullivan D, Buck M, Noguchi T, Curtis J . Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell. 2015; 162(6):1229-41. PMC: 4864363. DOI: 10.1016/j.cell.2015.08.016. View

Hosseinkhani N, Derakhshani A, Shadbad M, Argentiero A, Racanelli V, Kazemi T . The Role of V-Domain Ig Suppressor of T Cell Activation (VISTA) in Cancer Therapy: Lessons Learned and the Road Ahead. Front Immunol. 2021; 12:676181. PMC: 8172140. DOI: 10.3389/fimmu.2021.676181. View

von Locquenghien M, Rozalen C, Celia-Terrassa T . Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response. J Clin Invest. 2021; 131(1). PMC: 7773346. DOI: 10.1172/JCI143296. View

10.

Derosa L, Routy B, Thomas A, Iebba V, Zalcman G, Friard S . Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer. Nat Med. 2022; 28(2):315-324. PMC: 9330544. DOI: 10.1038/s41591-021-01655-5. View

11.

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

12.

Limagne E, Richard C, Thibaudin M, Fumet J, Truntzer C, Lagrange A . Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients. Oncoimmunology. 2019; 8(4):e1564505. PMC: 6422400. DOI: 10.1080/2162402X.2018.1564505. View

13.

Ghonim M, Ibba S, Tarhuni A, Errami Y, Luu H, Dean M . Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1 immunotherapy in colon cancer. J Immunother Cancer. 2021; 9(1). PMC: 7839867. DOI: 10.1136/jitc-2020-001643. View

14.

McGranahan N, Rosenthal R, Hiley C, Rowan A, Watkins T, Wilson G . Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution. Cell. 2017; 171(6):1259-1271.e11. PMC: 5720478. DOI: 10.1016/j.cell.2017.10.001. View

15.

Trujillo J, Luke J, Zha Y, Segal J, Ritterhouse L, Spranger S . Secondary resistance to immunotherapy associated with β-catenin pathway activation or PTEN loss in metastatic melanoma. J Immunother Cancer. 2019; 7(1):295. PMC: 6839232. DOI: 10.1186/s40425-019-0780-0. View

16.

Hellmann M, Rizvi N, Goldman J, Gettinger S, Borghaei H, Brahmer J . Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2016; 18(1):31-41. PMC: 5476941. DOI: 10.1016/S1470-2045(16)30624-6. View

17.

Loi S, Dushyanthen S, Beavis P, Salgado R, Denkert C, Savas P . Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Clin Cancer Res. 2019; 25(4):1437. DOI: 10.1158/1078-0432.CCR-18-4264. View

18.

Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R . Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discov. 2017; 7(12):1420-1435. PMC: 5718941. DOI: 10.1158/2159-8290.CD-17-0593. View

19.

Weinstein I . Cancer. Addiction to oncogenes--the Achilles heal of cancer. Science. 2002; 297(5578):63-4. DOI: 10.1126/science.1073096. View

20.

Chen W, Teo J, Yau S, Wong M, Lok C, Che C . Chronic type I interferon signaling promotes lipid-peroxidation-driven terminal CD8 T cell exhaustion and curtails anti-PD-1 efficacy. Cell Rep. 2022; 41(7):111647. DOI: 10.1016/j.celrep.2022.111647. View